// Account brief

Novartis

Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source.

Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.

Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.

Scores

Theme Priority (1 to 10) Delivery (0 to 10) Stage Commitments made public, last 12 months R&D roles open on 6 Oct 2026
AI in drug discovery 5 claimed claimed 3 8
Research labs and data 5 4 live 1 10

The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.

Summary

Novartis scores 5 out of 10 for priority on both AI in drug discovery and research labs and data. On AI in drug discovery it describes AI work in target identification, chemistry and biologics, but the sources do not show an identifiable system in operation, so delivery shows as claimed rather than as a number. On research labs and data it scores 4 out of 10 for delivery: Data42, its research data platform in Biomedical Research, is shown running and connects clinical, molecular, preclinical and biology data. In the last 12 months partners announced three AI commitments, with Chai Discovery, Orionis and Relation Therapeutics, each quoting Novartis, and CAS announced a reaction informatics collaboration on research data; five AI commitments, including Isomorphic Labs and two Schrodinger agreements, came in the year before. On 6 October 2026 Novartis had 8 open R&D roles tied to AI in drug discovery and 10 tied to research labs and data, some counted under both, including Data42 engineers on Palantir Foundry and lab automation roles asking for experience with tools such as Biosero Orchestrator, Cellario and HighRes Biosolutions.

AI in drug discovery

What the company says: Priority 5

Our Novartis R&D leaders, Fiona Marshall ... have defined a clear strategy for how these technological advances should be integrated from end-to-end, across the R&D continuum.

Story: Smarter decisions at scale: How Novartis is using AI to advance R&D, 28 Jul 2026

Scaling AI across the value chain to unlock productivity and performance ... Target Discovery Engine ... Small molecule GenChem and optimization

Meet Novartis Management 2025 CEO presentation (investor event, London), 20 Nov 2025, p. 29

What it shows running: Delivery claimed, claimed

This is playing out in focused initiatives across Novartis R&D: Target identification and validation: AI models can integrate evidence from human genetic and multi-omic datasets

Story: Smarter decisions at scale: How Novartis is using AI to advance R&D, 28 Jul 2026

Reviewed AI use case on “New Target Identification”, “Driving Translation through Data Science and AI”, “Present and Future of AI Augmented Chemistry”, and “AI/ML in Biologics”

Novartis Annual Report 2025 (Form 20-F format; AR and 20-F counted as one source), 4 Feb 2026, p. 125

These efforts are shifting how teams work so they’re spending less time sifting through data and more time on creative iteration and decision-making.

Story: Smarter decisions at scale: How Novartis is using AI to advance R&D, 28 Jul 2026

Commitments made public in the last 12 months: 3

  • Chai Discovery antibody design models: Announced collaboration under which Novartis will gain access to Chai AI antibody design models across multiple targets. New, announced, 13 Jul 2026. Published by: partner release, company quoted.
  • Orionis Allo-Glue molecular glue collaboration: Orionis announced a renewed and expanded collaboration under which its Allo-Glue platform and AI-driven discovery engine will be used for molecular glue discovery. Expanded, announced, 10 Jun 2026. Published by: partner release, company quoted.
  • Relation Therapeutics atopic disease target discovery: Multi-programme AI target discovery collaboration in atopic diseases, including equity investment. New, announced, 9 Dec 2025. Published by: partner release, company quoted.

Commitments made public in the year before: 5

  • Monte Rosa molecular glue degrader collaborations: Second Monte Rosa deal under which its AI/ML QuEEN engine will be applied to design immune molecular glue degraders. Expanded, announced, 15 Sep 2025. Published by: media only.
  • ProFound Therapeutics cardiovascular target discovery: Four-year cardiovascular target discovery partnership under which ProFound's ProFoundry platform, aided by predictive AI models, will be applied. New, announced, 26 Jun 2025. Published by: media only.
  • Isomorphic Labs AI drug design collaboration: Isomorphic expands strategic research collaboration with up to three additional programmes. Expanded, announced, 18 Feb 2025. Published by: partner only.
  • Schrodinger expanded software licence: Expanded three-year licence for Schrodinger modelling and enterprise informatics platform. Expanded, operational, 12 Nov 2024. Published by: partner release, company quoted.
  • Schrodinger multi-target discovery collaboration: Multi-target discovery collaboration and licence under which Schrodinger's computational platform is to be applied to Novartis targets. New, announced, 12 Nov 2024. Published by: partner release, company quoted.

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 8

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Research labs and data

What the company says: Priority 5

As Chief Data and Digital Officer, I’m driven by the idea that data science and AI can help us understand disease

Story: The Day AI Made Me Rethink What Science Could Do (Christian Diehl), 23 Sep 2026

That question led me to develop what became Data42 within Biomedical Research

Story: The Day AI Made Me Rethink What Science Could Do (Christian Diehl), 23 Sep 2026

What it shows running: Delivery 4, live

Today, I’m proud to say that Data42 underpins our growing ecosystem of AI-driven research. By connecting clinical, molecular, preclinical and biology data, it enables us to tackle scientific questions across domains

Story: The Day AI Made Me Rethink What Science Could Do (Christian Diehl), 23 Sep 2026

Commitments made public in the last 12 months: 1

  • CAS AI-ready reaction informatics: CAS collaboration with Novartis Biomedical Research to make proprietary reaction data AI-ready and searchable. New, announced, 29 Sep 2026. Published by: partner only.

Commitments made public in the year before: 1

  • Schrodinger expanded software licence: Expanded three-year licence for Schrodinger modelling and enterprise informatics platform. Expanded, operational, 12 Nov 2024. Published by: partner release, company quoted.

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 10

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Technology named in these postings

Named as in use: Data42, Palantir Foundry.

Asked for as experience: Beckman Echo, Biosero Orchestrator, Cellario, CellTrio RoboCell, Denso robots, GNF Director, Green Button Go, HighRes Biosolutions, Staubli robots.

A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.

Two questions to investigate (Ortent's interpretation)

  1. Biomedical Research has a Chief Data and Digital Officer and is hiring for Data42 on Palantir Foundry and for AI-enabled software across lab workflows, while partners have announced reaction data work with CAS and an expanded Schrodinger licence. Who decides on additions to research data and lab software, and how do Data42, partner platforms and lab systems connect?
  2. Novartis combines AI partnerships, such as Chai and Schrodinger, with tools built in house, and research computing and enterprise AI platform roles sit outside R&D. Who decides between building, partnering and buying discovery AI tools, and how are research models and compute bought and funded?

Coverage limits

Search coverage is partial for every event type in both themes and both years, and no FY2026 annual report exists yet, so the latest year relies on the FY2025 report and interim material. The novartis.com newsroom has no keyword filter and was not fully listed, and some quarterly releases and investor presentations were not re-read. Fierce Biotech blocked access, so a May 2026 report on Biomedical Research roles is not used, and the ProFound and Monte Rosa deals rest on media copies because the primary releases were not read. Archived Novartis job postings show no openings field, so vacancy status could not be checked for every role.

// GET IN TOUCH

Clarity when it counts.

For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.

Request a 30-minute intro call